Osteonecrosis of the jaw associated with pembrolizumab

Published:January 01, 2023DOI:

      Statement of Clinical Relevance

      • We report a case of ONJ with pembrolizumab, a rare yet possibly emerging complication. The number of patients using pembrolizumab will likely continue to increase. We document this instance to better inform dental treatment around cancer patients undergoing pembrolizumab therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'